MX2023013081A - Composiciones de coronavirus e influenza y métodos para utilizarlas. - Google Patents
Composiciones de coronavirus e influenza y métodos para utilizarlas.Info
- Publication number
- MX2023013081A MX2023013081A MX2023013081A MX2023013081A MX2023013081A MX 2023013081 A MX2023013081 A MX 2023013081A MX 2023013081 A MX2023013081 A MX 2023013081A MX 2023013081 A MX2023013081 A MX 2023013081A MX 2023013081 A MX2023013081 A MX 2023013081A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- coronavirus
- detergent
- glycoprotein
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010022000 influenza Diseases 0.000 title abstract 3
- 241000004176 Alphacoronavirus Species 0.000 title 1
- 241000711573 Coronaviridae Species 0.000 abstract 3
- 101710154606 Hemagglutinin Proteins 0.000 abstract 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 3
- 101710176177 Protein A56 Proteins 0.000 abstract 3
- 239000003599 detergent Substances 0.000 abstract 3
- 239000000185 hemagglutinin Substances 0.000 abstract 3
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 241000712431 Influenza A virus Species 0.000 abstract 1
- 101710167605 Spike glycoprotein Proteins 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184727P | 2021-05-05 | 2021-05-05 | |
| US202163193356P | 2021-05-26 | 2021-05-26 | |
| US202163255685P | 2021-10-14 | 2021-10-14 | |
| US202263332537P | 2022-04-19 | 2022-04-19 | |
| PCT/US2022/027465 WO2022235663A1 (en) | 2021-05-05 | 2022-05-03 | Coronavirus and influenza compositions and methods for using them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013081A true MX2023013081A (es) | 2024-01-15 |
Family
ID=83901839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013081A MX2023013081A (es) | 2021-05-05 | 2022-05-03 | Composiciones de coronavirus e influenza y métodos para utilizarlas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220354944A1 (enExample) |
| EP (1) | EP4333885A4 (enExample) |
| JP (1) | JP2024516309A (enExample) |
| KR (1) | KR20240024064A (enExample) |
| AU (1) | AU2022270082A1 (enExample) |
| BR (1) | BR112023023035A2 (enExample) |
| CA (1) | CA3217591A1 (enExample) |
| IL (1) | IL308180A (enExample) |
| MX (1) | MX2023013081A (enExample) |
| TW (1) | TW202308685A (enExample) |
| WO (1) | WO2022235663A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2024174012A1 (pt) * | 2023-02-24 | 2024-08-29 | Instituto Butantan | Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal |
| EP4687968A1 (en) * | 2023-04-03 | 2026-02-11 | Novavax, Inc. | Coronavirus and influenza compositions and methods for using them |
| US20250085282A1 (en) * | 2023-09-11 | 2025-03-13 | Novavax, Inc. | Method for detecting anti-sars-cov-2 spike (s) immunoglobulins |
| US20250144200A1 (en) * | 2023-11-06 | 2025-05-08 | Novavax, Inc. | Intranasal immunogenic compositions |
| EP4670733A1 (en) * | 2024-06-27 | 2025-12-31 | Sanofi | METHODS FOR PREPARING VIRAL PROTEINS AND THEIR USES |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2826058C (en) * | 2011-02-04 | 2017-06-06 | Zoetis Llc | Compositions for canine respiratory disease complex |
| BR112016006122B1 (pt) * | 2013-09-19 | 2023-11-14 | Novavax, Inc | COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV) |
| CA2996007A1 (en) * | 2015-09-03 | 2017-03-09 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| CN120227451A (zh) * | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US20230070886A1 (en) * | 2020-01-27 | 2023-03-09 | Novavax, Inc. | Coronavirus vaccine formulations |
| US12194089B2 (en) * | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| WO2021211749A1 (en) * | 2020-04-14 | 2021-10-21 | The Regents Of The University Of California | Multi-epitope pan-coronavirus vaccine compositions |
| GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| CN112546211A (zh) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
| CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
| CN113185613B (zh) * | 2021-04-13 | 2022-09-13 | 武汉大学 | 新型冠状病毒s蛋白及其亚单位疫苗 |
-
2022
- 2022-05-03 MX MX2023013081A patent/MX2023013081A/es unknown
- 2022-05-03 BR BR112023023035A patent/BR112023023035A2/pt unknown
- 2022-05-03 JP JP2023568063A patent/JP2024516309A/ja active Pending
- 2022-05-03 IL IL308180A patent/IL308180A/en unknown
- 2022-05-03 WO PCT/US2022/027465 patent/WO2022235663A1/en not_active Ceased
- 2022-05-03 EP EP22799423.3A patent/EP4333885A4/en active Pending
- 2022-05-03 CA CA3217591A patent/CA3217591A1/en active Pending
- 2022-05-03 KR KR1020237041628A patent/KR20240024064A/ko active Pending
- 2022-05-03 AU AU2022270082A patent/AU2022270082A1/en active Pending
- 2022-05-04 US US17/736,452 patent/US20220354944A1/en active Pending
- 2022-05-05 TW TW111116974A patent/TW202308685A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023023035A2 (pt) | 2024-01-23 |
| EP4333885A1 (en) | 2024-03-13 |
| KR20240024064A (ko) | 2024-02-23 |
| IL308180A (en) | 2024-01-01 |
| AU2022270082A1 (en) | 2023-11-16 |
| TW202308685A (zh) | 2023-03-01 |
| CA3217591A1 (en) | 2022-11-10 |
| JP2024516309A (ja) | 2024-04-12 |
| WO2022235663A1 (en) | 2022-11-10 |
| US20220354944A1 (en) | 2022-11-10 |
| EP4333885A4 (en) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013081A (es) | Composiciones de coronavirus e influenza y métodos para utilizarlas. | |
| AR089578A1 (es) | Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion | |
| MX2011009930A (es) | Metodos y composiciones para inmunizacion contra virus. | |
| EA200900784A1 (ru) | Вакцины, включающие антиген из четырех штаммов вируса гриппа | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| MX347210B (es) | Vacunas combinadas para prevención de infecciones por virus porcino. | |
| CL2018002474A1 (es) | Composición oralmente administrable. | |
| MX2018007198A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| CO5680456A2 (es) | Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis | |
| ES2723050T3 (es) | Variantes de fitasa termoestables | |
| CL2021003388A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| MX2019004319A (es) | Acorde de floracion de alto rendimiento, alto impacto. | |
| MX2018016037A (es) | Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa. | |
| CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
| PE20210651A1 (es) | Vacunas contra virus de la gripe y usos de las mismas | |
| BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
| MX363464B (es) | Vacunas contra influenza h5. | |
| BR112014024460A8 (pt) | Articulação mecânica, e, método para fabricar um membro estrutural de amortecimento | |
| MX2024006589A (es) | Formulaciones de vacunas contra el coronavirus. | |
| CO2020000021A2 (es) | Método para preparar reserva de cepas víricas de trabajo para la influenza, método para preparar la vacuna contra la influenza usando la misma reserva de cepas, y la reserva de cepas víricas preparadas por el mismo método | |
| PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| AR125781A1 (es) | Composiciones de coronavirus e influenza y métodos de utilizarlas | |
| CO2023004963A2 (es) | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden | |
| MX2020000790A (es) | Pautas para el tratamiento de infecciones por el vih y sida. |